Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 7/20 | 0.40 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.34 |
| ▸ | KDR | P35968 | 9/20 | 0.34 |
| ▸ | FLT1 | P17948 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | SMO | Q99835 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CFTR | P13569 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30203040 | 1.00 | BRAF (0.40) | BRAFLIPGCYP17A1MAPK14KDR | |
| SCHEMBL23355350 | 0.88 | MAPK14 (0.35) | MAPK14KDRMAPTSMOSMN1; SMN2 | |
| SCHEMBL29834735 | 0.85 | CYP17A1 (0.36) | BRAFCYP17A1MAPK14KDRFLT1 | |
| SCHEMBL21612850 | 0.82 | MAPT (0.33) | LIPGMAPTSMOCFTR | |
| SCHEMBL29834719 | 0.82 | BRAF (0.43) | BRAFCYP17A1MAPK14KDRFLT1 | |
| SCHEMBL23368199 | 0.81 | KDM4E (0.40) | BRAFLIPGCYP17A1MAPK14KDR | |
| SCHEMBL30203050 | 0.81 | KDM4E (0.40) | BRAFLIPGCYP17A1MAPK14KDR | |
| SCHEMBL21612849 | 0.79 | MAPT (0.33) | MAPTSMN1; SMN2 | |
| SCHEMBL23355478 | 0.78 | MAPT (0.34) | MAPTSMO | |
| SCHEMBL24926748 | 0.78 | BACE1 (0.36) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230025510-A1 | BIARYL ETHER-TYPE QUINAZOLINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230025510-A1 | BIARYL ETHER-TYPE QUINAZOLINE DERIVATIVES | ERBB2, EGFR, ERBB3 | BRAF 28/4885LIPG 3174/4885CYP17A1 599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.